Group sales rose +6% (+9% at CC) to USD4,205m and the gross profit margin strongly improved from 29.9% to 31.3%. EBIT increased +7% to USD540m and net profit attributable to shareholders came in at USD228m after USD210m. Operating CF melted from USD447m to USD180m, hit by a swing in NWC (USD-299m after USD7m), which was triggered by an adjustment in invoicing and the timing of payroll payments in the US. DSO increased to 74 days (Q1 15: 71; Q4 15: 71). Investing CF moved from USD-208m to USD-

03 May 2016
A shining US

Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
A shining US
Fresenius Medical Care AG (FME:WBO) | 0 0 0.7% | Mkt Cap: 26,769m
- Published:
03 May 2016 -
Author:
Martin Schnee -
Pages:
3 -
Group sales rose +6% (+9% at CC) to USD4,205m and the gross profit margin strongly improved from 29.9% to 31.3%. EBIT increased +7% to USD540m and net profit attributable to shareholders came in at USD228m after USD210m. Operating CF melted from USD447m to USD180m, hit by a swing in NWC (USD-299m after USD7m), which was triggered by an adjustment in invoicing and the timing of payroll payments in the US. DSO increased to 74 days (Q1 15: 71; Q4 15: 71). Investing CF moved from USD-208m to USD-